SCHEMBL20568152

SCHEMBL20568152

CCc1c(C(=O)OC)[nH]c(-c2ccccc2)c1I

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.42
POLB P06746 1/20 0.42
ATM Q13315 1/20 0.42
LMNA P02545 2/20 0.41
NR4A2 P43354 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ALDH1A1 P00352 5/20 0.39
GAA P10253 4/20 0.39
HPGD P15428 1/20 0.39
NPSR1 Q6W5P4 2/20 0.39
MAPT P10636 1/20 0.39
STAT1 P42224 1/20 0.39
KDM4E B2RXH2 2/20 0.39
TSHR P16473 2/20 0.39
AXL P30530 1/20 0.39
HTT P42858 2/20 0.38
CCNC P24863 1/20 0.38
CDK8 P49336 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PADI4 Q9UM07 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20568399 0.89 LMNA (0.41) RAB9APOLBATMLMNAL3MBTL1
SCHEMBL20568130 0.78 LMNA (0.48) RAB9ALMNANR4A2ALDH1A1GAA
SCHEMBL20568371 0.77 CCNC (0.43) RAB9ALMNAALDH1A1GAAHPGD
SCHEMBL20567844 0.77 ALDH1A1 (0.44) RAB9ALMNAALDH1A1GAAHPGD
SCHEMBL13933298 0.75 NR4A2 (0.53) POLBATMNR4A2L3MBTL1ALDH1A1
SCHEMBL13984204 0.73 LMNA (0.45) RAB9ALMNANR4A2ALDH1A1GAA
SCHEMBL20569062 0.72 SMN1; SMN2 (0.37) LMNAALDH1A1GAAHPGDNPSR1
SCHEMBL7380594 0.72 KDM4E (0.60) RAB9ALMNANR4A2ALDH1A1GAA
SCHEMBL10991117 0.72 LMNA (0.59) RAB9APOLBLMNANR4A2ALDH1A1
SCHEMBL4491006 0.71 ALDH1A1 (0.56) RAB9ALMNANR4A2ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11413272-B2 Inhibitors of metallo-beta-lactamases OXFORD UNIVERSITY INNOVATION LIMITED 2022-08-16 US disclosed
EP-3630728-B1 INHIBITORS OF METALLO-BETA-LACTAMASES UNIV OXFORD INNOVATION LTD (GB) 2022-07-27 EP disclosed
US-20210137884-A1 INHIBITORS OF METALLO-BETA-LACTAMASES OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2021-05-13 US disclosed
EP-3630728-A1 INHIBITORS OF METALLO-BETA-LACTAMASES Oxford University Innovation Limited (GB) 2020-04-08 EP disclosed
WO-2018215799-A1 INHIBITORS OF METALLO-BETA-LACTAMASES OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2018-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11413272-B2 Inhibitors of metallo-beta-lactamases MGAM, GAA, ALPI RAB9A 1767/4885POLB 342/4885ATM 3914/4885
US-20210137884-A1 INHIBITORS OF METALLO-BETA-LACTAMASES MGAM, GAA, ALPI RAB9A 1767/4885POLB 342/4885ATM 3914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.